UPDATE 2-FDA approves two treatments from Roche, Boehringer for fatal lung disorder
* First-ever U.S. approvals for idiopathic pulmonary fibrosis
* Roche's Esbriet to be priced at about $94,000 per year
* Esbriet expected to generate sales of about $1.04 billion in 2019 (Adds pricing details for Roche drug)
By Natalie Grover
Oct 15 (Reuters) - The U.S. health regulator approved two treatments for use in idiopathic pulmonary fibrosis (IPF), marking its first-ever approvals for the fatal lung disease that has no clear etiology and no cure.
The first, Esbriet, was developed by InterMune Inc, which Switzerland-based Roche Holding AG agreed to buy for $8.3 billion in August, banking largely on the treatment's potential.
Privately held German drugmaker Boehringer Ingelheim's rival drug nintedanib, which will be sold under the brand name Ofev, also won U.S. Food and Drug Administration approval on Wednesday. (1.usa.gov/1qwyxk5)
The agency's decision marks a crucial milestone in the management of the disease, which affects about 100,000 people in the United States.
IPF is characterized by scarring that thickens the lining of the lungs, causing an irreversible loss of the tissue's ability to transport oxygen. Continued...